Biotricity Inc. (BTCY) Announces Q2 Loss, Falls Short of Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy VEEV?
Source: NASDAQ.COM
Quarterly Performance: Biotricity Inc. (BTCY) reported a quarterly loss of $0.03 per share, outperforming the Zacks Consensus Estimate of a loss of $0.08, marking a 62.5% earnings surprise. The company also posted revenues of $3.89 million, slightly missing expectations but showing growth from $3.27 million a year ago.
Stock Outlook: Biotricity shares have increased by approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's 14.6% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, while the estimate for the current fiscal year is -$0.32 on $15.8 million in revenues. The mixed trend in estimate revisions may influence future stock performance.
Industry Context: Biotricity operates within the Medical Info Systems industry, which ranks in the top 31% of Zacks industries. The performance of the stock may be affected by broader industry trends, with Veeva Systems (VEEV) set to report its quarterly results soon, expected to show a year-over-year earnings increase.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 181.450
Low
222.00
Averages
317.10
High
380.00
Current: 181.450
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and the strategic business functions from research and development (R&D) through commercialization. Its four product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes, and partners across content management, training, quality management, assurance, and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Veeva Data Cloud is a data platform comprised of connected reference data, deep data, and transaction data.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veeva Systems Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Veeva Systems is set to release its Q4 fiscal year 2024 earnings on March 4 after market close, with consensus EPS estimates at $1.94, reflecting an 11.5% year-over-year growth, indicating the company's ongoing growth potential in the biopharmaceutical sector.
- Revenue Expectations: The anticipated revenue for Q4 is $810.95 million, representing a 12.5% year-over-year increase, which suggests strong performance in customer demand and market share, potentially solidifying its leadership position in the industry.
- Performance Beat Record: Over the past two years, Veeva has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing a consistent performance that enhances investor confidence and may positively impact stock prices.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates have experienced four upward revisions and one downward, indicating a market optimism regarding Veeva's future performance that could attract more investor interest.
See More
Veeva Vault CRM Leads Life Sciences Industry with Over 125 Customers
- Customer Milestone: Veeva Vault CRM is now live with over 125 customers, including multiple top 20 biopharma companies, demonstrating its broad acceptance and application within the life sciences sector.
- Accelerated Industry Transformation: With the introduction of Veeva AI, Vault CRM is accelerating the industry's shift towards agentic customer relationship management, providing deep industry functionality and compliance to help clients optimize complex customer engagements.
- Lifecycle Support: Vault CRM offers the foundational support that commercial and medical teams need to manage the full product lifecycle, from market preparation to optimizing mature brand performance, ensuring effective management of complex customer relationships.
- Infrastructure Upgrade: Veeva has moved the end-of-support date for Veeva CRM from September 2030 to December 2029, reflecting the company's commitment to Vault CRM and customer success, further solidifying its leadership position in the industry.
See More
Analysis & Outlook: A Reality Assessment
- Market Reaction: Stocks opened significantly lower, indicating a shift away from the previous "ignore geopolitics" mindset.
- Recovery Trend: By late morning, there was a noticeable recovery in stock prices, suggesting some stabilization in the market.
See More
Investment Potential of Eli Lilly and Veeva Systems
- Eli Lilly's Growth Momentum: Eli Lilly has demonstrated revenue growth rates exceeding mid-double digits in recent quarters, significantly outperforming large pharmaceutical companies, showcasing its leadership in the anti-obesity drug market, with new drug launches expected to further solidify its market share.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, with the anticipated launch of the oral GLP-1 drug forglipron this year and additional approvals expected in the coming years, enhancing the diversity of its product pipeline.
- Veeva Systems' Market Opportunity: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, with a goal to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, reflecting its strong competitive position in a rapidly growing market.
- Growth Potential in Cloud Market: Veeva Systems estimates an addressable market of $20 billion, significantly higher than its trailing 12-month revenue of $3.1 billion, indicating substantial growth opportunities ahead, prompting investors to consider buying at current low levels.
See More
Eli Lilly and Veeva Systems' Growth Potential
- Strong Growth for Eli Lilly: Eli Lilly has achieved mid-double-digit revenue growth rates in recent quarters, significantly exceeding the pharmaceutical industry average, demonstrating its robust competitive position and future growth potential.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, and the anticipated launch of the oral GLP-1 drug forglipron this year will further solidify its leadership in the rapidly growing anti-obesity market.
- Market Opportunities for Veeva Systems: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, and aims to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, showcasing its strong competitive edge in the large cloud market.
- Optimistic Industry Outlook: Despite intensified competition, Veeva Systems' high switching costs and unique market positioning provide ample growth opportunities, with an addressable market estimated at $20 billion, significantly surpassing its current revenue of $3.1 billion.
See More
Veeva Vault CRM Surpasses 125 Clients in Life Sciences
- Significant Client Growth: Veeva Vault CRM has now attracted over 125 clients, including several of the top 20 global biopharmaceutical companies, demonstrating its strong appeal and market demand in the life sciences sector.
- Industry Leadership: The success of Vault CRM, coupled with the launch of Veeva AI, is driving the industry's shift towards intelligent customer relationship management, enhancing customer engagement and business efficiency.
- Support Timeline Adjustment: Veeva has moved the end-of-support date for Veeva CRM from September 2030 to December 2029, indicating the company's strategic focus on Vault CRM and its positioning in the market.
- Comprehensive Solution: Vault CRM serves as the core technology platform for biopharmaceutical companies, encompassing event management, service centers, and patient CRM functionalities, aimed at optimizing customer relationship management and product lifecycle support.
See More
Veeva Systems Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Veeva Systems is set to release its Q4 fiscal year 2024 earnings on March 4 after market close, with consensus EPS estimates at $1.94, reflecting an 11.5% year-over-year growth, indicating the company's ongoing growth potential in the biopharmaceutical sector.
- Revenue Expectations: The anticipated revenue for Q4 is $810.95 million, representing a 12.5% year-over-year increase, which suggests strong performance in customer demand and market share, potentially solidifying its leadership position in the industry.
- Performance Beat Record: Over the past two years, Veeva has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing a consistent performance that enhances investor confidence and may positively impact stock prices.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates have experienced four upward revisions and one downward, indicating a market optimism regarding Veeva's future performance that could attract more investor interest.
See More
Veeva Vault CRM Leads Life Sciences Industry with Over 125 Customers
- Customer Milestone: Veeva Vault CRM is now live with over 125 customers, including multiple top 20 biopharma companies, demonstrating its broad acceptance and application within the life sciences sector.
- Accelerated Industry Transformation: With the introduction of Veeva AI, Vault CRM is accelerating the industry's shift towards agentic customer relationship management, providing deep industry functionality and compliance to help clients optimize complex customer engagements.
- Lifecycle Support: Vault CRM offers the foundational support that commercial and medical teams need to manage the full product lifecycle, from market preparation to optimizing mature brand performance, ensuring effective management of complex customer relationships.
- Infrastructure Upgrade: Veeva has moved the end-of-support date for Veeva CRM from September 2030 to December 2029, reflecting the company's commitment to Vault CRM and customer success, further solidifying its leadership position in the industry.
See More
Analysis & Outlook: A Reality Assessment
- Market Reaction: Stocks opened significantly lower, indicating a shift away from the previous "ignore geopolitics" mindset.
- Recovery Trend: By late morning, there was a noticeable recovery in stock prices, suggesting some stabilization in the market.
See More
Investment Potential of Eli Lilly and Veeva Systems
- Eli Lilly's Growth Momentum: Eli Lilly has demonstrated revenue growth rates exceeding mid-double digits in recent quarters, significantly outperforming large pharmaceutical companies, showcasing its leadership in the anti-obesity drug market, with new drug launches expected to further solidify its market share.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, with the anticipated launch of the oral GLP-1 drug forglipron this year and additional approvals expected in the coming years, enhancing the diversity of its product pipeline.
- Veeva Systems' Market Opportunity: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, with a goal to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, reflecting its strong competitive position in a rapidly growing market.
- Growth Potential in Cloud Market: Veeva Systems estimates an addressable market of $20 billion, significantly higher than its trailing 12-month revenue of $3.1 billion, indicating substantial growth opportunities ahead, prompting investors to consider buying at current low levels.
See More
Eli Lilly and Veeva Systems' Growth Potential
- Strong Growth for Eli Lilly: Eli Lilly has achieved mid-double-digit revenue growth rates in recent quarters, significantly exceeding the pharmaceutical industry average, demonstrating its robust competitive position and future growth potential.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, and the anticipated launch of the oral GLP-1 drug forglipron this year will further solidify its leadership in the rapidly growing anti-obesity market.
- Market Opportunities for Veeva Systems: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, and aims to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, showcasing its strong competitive edge in the large cloud market.
- Optimistic Industry Outlook: Despite intensified competition, Veeva Systems' high switching costs and unique market positioning provide ample growth opportunities, with an addressable market estimated at $20 billion, significantly surpassing its current revenue of $3.1 billion.
See More
Veeva Vault CRM Surpasses 125 Clients in Life Sciences
- Significant Client Growth: Veeva Vault CRM has now attracted over 125 clients, including several of the top 20 global biopharmaceutical companies, demonstrating its strong appeal and market demand in the life sciences sector.
- Industry Leadership: The success of Vault CRM, coupled with the launch of Veeva AI, is driving the industry's shift towards intelligent customer relationship management, enhancing customer engagement and business efficiency.
- Support Timeline Adjustment: Veeva has moved the end-of-support date for Veeva CRM from September 2030 to December 2029, indicating the company's strategic focus on Vault CRM and its positioning in the market.
- Comprehensive Solution: Vault CRM serves as the core technology platform for biopharmaceutical companies, encompassing event management, service centers, and patient CRM functionalities, aimed at optimizing customer relationship management and product lifecycle support.
See More
